Lupus & antiphospholipid syndrome
Association of anti-β2-glycoprotein I/HLA-DR complex antibody with arterial thrombosis in female patients with systemic rheumatic diseases
Main finding · Arterial thrombosisResult — go to the resultOdds ratio 5.13 95% CI 2.85–9.24Authors' conclusion
Anti-β2GPI/HLA-DR antibodies are associated with arterial thrombosis in female patients with systemic rheumatic diseases.
Study context
- Population
- Women with systemic rheumatic diseases, including 66 (obstetric or thrombotic) antiphospholipid syndrome (APS), 13 primary APS and 78 asymptomatic aPL carriers77 with arterial thrombosis
- Participants
- 704 women
- Exposure
- Anti-β2GPI/HLA-DR antibody positivity vs negativity
- Outcome
- Arterial thrombosis
Methodological detailsROC analysis, multivariate logistic analysis
- ROC analysis
- Multivariate logistic analysis
Main finding
As reported in the abstract
Odds ratio
5.13
95% CI 2.85–9.24
By group
Anti-β2GPI/HLA-DR positive
- Sensitivity
- 33.8%
- Specificity
- 91.4%
- AUC
- 0.6009
Anti-β2GPI/HLA-DR positive
Sensitivity33.8%
Specificity91.4%
AUC0.6009
Anti-β2GPI/HLA-DR positivevs Anti-β2GPI/HLA-DR negative
OR 5.13 (95% CI 2.85–9.24)
Observational data: associations, not effects.
Further findings
Anti-β2GPI/HLA-DR titers by thrombosis and aPL profile
- High titers in 14 patients with both arterial and venous thrombosis, and in patients with adjusted global antiphospholipid syndrome score (aGAPSS) > 10 or triple-positive aPL profiles
Original publication
Association of anti-β2-glycoprotein I/HLA-DR complex antibody with arterial thrombosis in female patients with systemic rheumatic diseases. Arthritis Res Ther. Published 6 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →